查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1560018

僵直性脊椎炎治疗市场报告：2030 年趋势、预测与竞争分析

Ankylosing Spondylitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

僵直性脊椎炎治疗的趋势与预测

预计到 2030 年，全球僵直性脊椎炎治疗市场将达到 84 亿美元，2024 年至 2030 年复合年增长率为 6.5%。这个市场的关键驱动因素是僵直性脊椎炎发生率的上升、对该疾病的认识和诊断的提高以及僵直性脊椎炎治疗的进步。全球僵直性脊椎炎治疗市场前景广阔，医院药局、零售药局、网路药局市场充满机会。

  • Lucintel 预测，由于僵直性脊椎炎的成长，非类固醇抗发炎药物在预测期内将继续成为较大的细分市场。
  • 由于零售药局数量不断增加且患者更容易获得，预计零售药局仍将是市场上最大的部分。
  • 由于老年人口不断增长和政府的支持措施，预计北美在预测期内仍将是最大的地区。

僵直性脊椎炎治疗市场的新趋势

僵直性脊椎炎治疗市场正在见证许多新兴趋势，这些趋势将塑造患者管理和治疗的未来。

  • 生技药品创新：作用于明确发炎途径的新生技药品（例如 TNF 和 IL-17）的开发彻底改变了 AS 的治疗。事实证明，这些药物比传统治疗方法更有效且副作用更少。
  • 生物相似药的扩展：现有生技药品的生物仿製药正在被引入，并且总体上变得更加实惠和可用。世界各地越来越多的患者正在获得先进的治疗，特别是在成本敏感的市场。
  • 个人化医疗：遗传和分子生物学研究的进步使治疗变得越来越个人化。根据个体的遗传特征和疾病特征量身订做治疗治疗方法可以提高疗效并最大限度地减少毒性。
  • 数位健康整合：穿戴式装置和行动应用等数位健康科技在疾病监测和管理中发挥越来越大的作用。这些工具提供有关疾病进程和治疗效果的即时信息，可以帮助做出更好的临床决策。
  • 加强患者支持计划：人们越来越关注全面的患者支持计划，包括教育、自我管理工具和心理支持。这些计划旨在提高治疗依从性和整体生活品质。

新兴市场趋势正在透过引入新的治疗方法、改善可及性和加强患者照护来改变僵直性脊椎炎治疗市场的面貌。

僵直性脊椎炎治疗市场的最新趋势

僵直性脊椎炎治疗市场的最新发展反映了对这种慢性疾病的管理的改善，新药和新治疗方法的重大发展。

  • 新的生技药品製剂最近，针对 TNF 和 IL-17 的新生技药品已获得核准，扩大了治疗选择。这些新药已表现出卓越的功效和安全性，并且满足了对常规治疗方法无效的患者的需求。
  • 生物相似药的推出 生物相似药在中国和印度市场的推出使先进的治疗方法变得越来越便宜。这项进展预计将改善患者获得有效生技药品的机会并加强整体疾病管理。
  • 个人化治疗方法：基因研究的进步正在带来个人化治疗方法。基于遗传和分子特征的客製化治疗可最大限度地减少副作用，从而改善治疗结果。
  • 数位健康解决方案：穿戴式装置和行动应用程式等数位健康工具的整合正在改善疾病监测和管理。这些技术提供即时见解并支援个人化治疗计划。
  • 提高意识和获取机会：同样，关于 AS 的公众意识提升宣传活动，包括改善印度等新兴市场的卫生基础设施，正在进一步扩大获得有效干预措施的机会。这是改善服务欠缺地区患者治疗效果的必要步骤。

僵直性脊椎炎治疗市场正在随着这些不同的开拓向前发展，着眼于扩大选择、改善可及性和开发个人化医疗。

僵直性脊椎炎治疗市场的策略成长机会

僵直性脊椎炎治疗市场存在多种不同应用的策略成长机会。这也反映出对创新解决方案和改善患者照护的需求。

  • 扩大生技药品疗法：新生物疗法的开发和商业化具有巨大的成长潜力。事实上，这些治疗方法由于其效率和解决与 AS 管理相关的未满足需求的能力而需求量很大。
  • 生物相似药市场的成长：生物相似药市场的成长为改善获得有效 AS 治疗的机会开闢了前景。生物相似药的市场开拓和销售将促进更广泛的可用性和更低的成本，特别是在成本敏感地区。
  • 个人化医疗的进步：对个人化医疗策略（例如基因分析和分子分析）的日益关注是一个机会领域。事实证明，根据患者个别需求量身定制的治疗方法更有效、更容易接受，因此增加了对更个人化选择的需求。
  • 数位健康整合：这是使用数位健康技术进行疾病监测和管理的一个日益出现的机会。穿戴式装置和行动应用程式的开发和整合有助于改善患者的治疗效果和治疗依从性。
  • 病患支援计划：设计得更好的病患支援计划，包括教育、自我管理工具和心理支持，有可能提高治疗依从性和生活品质。对此类计划的更好投资将改善整体疾病管理。

所有这些机会正在改变治疗的创新、可及性和质量，塑造僵直性脊椎炎治疗市场。

僵直性脊椎炎治疗市场的驱动因素与挑战

与僵直性脊椎炎治疗市场相关的市场成长和挑战包括市场驱动因素/挑战以及由技术进步、经济因素和监管考虑组成的市场限制。

推动僵直性脊椎炎治疗市场的因素包括：

1.生技药品创新：我承诺，针对 TNF 和 IL-17 的新型生技药品是市场驱动因素，可提供更有效、更安全的治疗方法，满足未满足的需求并改善治疗结果。

2.生物相似药的广泛采用：随着生物相似药使AS治疗变得更便宜、更容易获得，这一趋势将扩大市场并使更多的患者群体能够获得先进的治疗。

3. 个人化医疗的进步：利用遗传和分子分析的个人化治疗方法的发展将提高治疗的有效性。这些进步推动了对改善患者治疗效果的客製化治疗的需求。

4. 提高意识和采用：提高新兴市场对 AS 治疗的认识和可近性将增加市场占有率。医疗基础设施的改善和病患教育的改善使得管理更加完善。

僵直性脊椎炎治疗市场面临的挑战如下：

1. 新疗法的高成本：新生技药品和个人化治疗的高成本使一些患者无法负担。这是需要注意的一个重要方面，以确保此类治疗方法的采用和推广。

2. 监管障碍：由于新的治疗方案尚未出现，这些新疗法的监管要求将难以满足。遵守合规性法规有助于市场准入和产品核可。

3.市场竞争：製药企业竞争激烈，影响市场占有率与价格。因此，保持竞争力需要在产品和服务方面不断创新和差异化。

这些市场驱动因素/挑战影响技术进步、市场活力和监管合规性，从而塑造僵直性脊椎炎治疗市场。有效解决这些因素对于利用机会和应对市场复杂性至关重要。

节段性僵直性脊椎炎治疗

本研究按药物类别、分销管道和地区提供了僵直性脊椎炎治疗的全球预测。

僵直性脊椎炎治疗市场的国家展望

僵直性脊椎炎治疗市场的开拓没有停止的迹象，药物开发和个人化医疗正在扩大。最近的一系列创新旨在解决未满足的需求并改善患者的治疗效果。美国、中国、德国、印度和日本的发展反映出药物治疗和支持性护理策略的显着进步。

  • 美国：过去 20 年来，许多针对 TNF 和 IL-17 的新型生技药品已上市。这些新药物具有更好的疗效和安全性，显着改善了 AS 患者的治疗。
  • 中国：中国也透过在现有的生技药品治疗中引入生物相似药来扩大其治疗选择。这将改善 AS 患者的可近性和负担能力，并有助于有效治疗方法的广泛使用。
  • 德国：在德国，新药标靶和个人化治疗方法的研发研究正在兴起。遗传和分子生物学研究的进步正在为僵直性脊椎炎带来更好的治疗选择。
  • 印度：在印度，人们对僵直性脊椎炎新治疗方法的认识和利用正在增加。 TNF 抑制剂的可用性和医疗基础设施的改善改善了患者的可近性和可用性。
  • 日本：在日本，人们关注新治疗方法以及数位健康在 AS 管理中的整合。最近，穿戴式装置已被用于监测疾病进展和治疗结果。

常问问题

Q1.市场规模有多大？

答：到2030年，全球僵直性脊椎炎治疗市场预计将达到84亿美元。

Q2.市场成长预测如何？

答：2024年至2030年，全球僵直性脊椎炎治疗市场预计将以6.5%的复合年增长率成长。

Q3.影响市场成长的关键驱动因素有哪些？

答：这个市场的主要驱动力是僵直性脊椎炎发生率的上升、对该疾病的认识和诊断的提高以及僵直性脊椎炎治疗的进步。

Q4.市场的主要细分市场有哪些？

答：僵直性脊椎炎治疗市场前景广阔，医院药局、零售药局、网路药局市场都有机会。

Q5.市场上主要企业有哪些？

答：治疗僵直性脊椎炎的主要企业有：

  • Novartis
  • Amgen
  • Boehringer Ingelheim International
  • UCB Biopharma
  • AbbVie

Q6.未来最大的细分市场是什么？

答：Lucintel 预计，由于僵直性脊椎炎的成长，非类固醇抗发炎药物在预测期内仍将占据更大的市场份额。

Q7. 未来五年预计哪个地区的市场最大？

答：由于老年人口不断增长以及政府的支持措施，北美在预测期内仍将是最大的地区。

Q8. 可以客製化报告吗？

答：是的，Lucintel 列出了 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球僵直性脊椎炎治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 僵直性脊椎炎治疗的全球市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类别分類的僵直性脊椎炎治疗的全球市场
    • NSAIDs
    • 肿瘤坏死因子抑制剂
    • 其他的
  • 按分销管道分類的全球僵直性脊椎炎治疗市场
    • 医院药房
    • 零售药房
    • 网路药房

第四章 2018-2030年区域市场趋势及预测分析

  • 全球僵直性脊椎炎治疗市场区域分布
  • 北美僵直性脊椎炎治疗市场
  • 欧洲僵直性脊椎炎治疗市场
  • 亚太地区僵直性脊椎炎治疗市场
  • 其他地区僵直性脊椎炎治疗市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按药物类别分類的全球僵直性脊椎炎治疗市场成长机会
    • 全球僵直性脊椎炎治疗市场成长机会（按分销管道）
    • 全球僵直性脊椎炎治疗市场按地区成长机会
  • 全球僵直性脊椎炎治疗市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大僵直性脊椎炎治疗市场的全球产能
    • 全球僵直性脊椎炎治疗市场的併购和合资企业
    • 认证和许可

第七章主要企业概况

  • Novartis
  • Amgen
  • Boehringer Ingelheim International
  • UCB Biopharma
  • AbbVie
简介目录

Ankylosing Spondylitis Treatment Trends and Forecast

The future of the global ankylosing spondylitis treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global ankylosing spondylitis treatment market is expected to reach an estimated $8.4 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are rising occurrence of ankylosing spondylitis, growing awareness and diagnosis of condition, and advancement in ankylosing spondylitis therapy.

  • Lucintel forecasts that NSAIDs will remain the larger segment over the forecast period due to growth of ankylosing spondylitis.
  • Within this market, retail pharmacy will remain the largest segment due to growing number of retail pharmacies and it is easy to reach for patients.
  • North America will remain the largest region over the forecast period due to growth of geriatric population and supportive government initiatives.

Emerging Trends in the Ankylosing Spondylitis Treatment Market

There are a number of emerging trends in the ankylosing spondylitis treatment market that will shape up the future of management and care for the patients.

  • Biologic Drug Innovation: Development of new biologics with activity on well-defined inflammatory pathways, including TNF and IL-17, has revolutionized the treatment of AS. These drugs are proving to be much more effective with fewer side effects than conventional therapies.
  • Biosimilars Expansion: Biosimilars of existing biologics are being introduced and overall, becoming more affordable and accessible. Advanced treatments are progressively becoming available for more patients from all over the world, especially in cost-sensitive markets.
  • Personalized Medicine: The advances in genetic and molecular studies result in treatment that increasingly becomes personalized. Tailoring therapies according to the genetic profile of an individual and the characteristics of a disease improves efficacy and minimizes toxicity.
  • Integration of Digital Health: Digital health technologies such as wearable devices and mobile applications are playing an increasing role in monitoring and managing diseases. The information these tools provide in real time about the progression of the disease course and the response of treatment thus helps inform better clinical decisions.
  • Enhanced Patient Support Programs: There is a growing focus on comprehensive patient support programs that include education, self-management tools, and psychological support. These programs aim to improve adherence to treatment and overall quality of life.

The trends growing in the market are changing the dimensions of the Ankylosing Spondylitis treatment market by introducing new therapies, improving access, and strengthening patient care.

Recent Developments in the Ankylosing Spondylitis Treatment Market

Recent advances within the Ankylosing Spondylitis treatment market show great development in new drugs and new therapeutic approaches, reflecting improvements in the management of this chronic condition.

  • New Biologic Approaches: The recent approval of new biologic agents targeting TNF and IL-17 has expanded the range of treatment options. These newer drugs offer superior efficacy and safety profiles, thereby responding to the needs of patients unable to respond to conventional therapies.
  • Biosimilars Launches: The launch of biosimilars in the markets of China and India has made advanced treatments increasingly more affordable. The development is likely to improve patient access to effective biologic therapies, thus enhancing overall disease management.
  • Personalized Treatment Approaches: Genetic research advances are seeing personalized treatment approaches. Treatment outcomes have improved, with customized therapies based on genetic and molecular profiles that minimize side effects.
  • Digital Health Solutions: The integration of digital health tools, such as wearable devices and mobile applications, is improving disease monitoring and management. These technologies provide real-time insights and support personalized treatment plans.
  • Increased Awareness and Access: Similarly, public awareness campaigns about AS, including the development of healthcare infrastructures in markets such as India, further widen access to effective interventions. A step much needed for improving patient results in underserved regions.

These various developments are impinging upon the Ankylosing Spondylitis treatment market with a view to expanding the options, increasing access, and developing personalized care.

Strategic Growth Opportunities for Ankylosing Spondylitis Treatment Market

A couple of strategic growth opportunities are present in the Ankylosing Spondylitis treatment market across various applications. This also reflects the need for innovative solutions and improvement in patient care.

  • Expansion of Biologic Treatments: Development and commercialization of new biologic therapies have huge growth potential. In fact, demand is high for these treatments due to their efficiency and capability in solving unmet needs related to AS management.
  • Biosimilars Market Growth: The growth in the biosimilars market opens up prospects for better access to effective AS treatments. Development and marketing of biosimilars will facilitate lower costs with wider availability, especially in cost-sensitive regions.
  • Development of Personalized Medicine: The attention to strategies for personalized medicine, such as genetic and molecular profiling, has been an area of opportunity. Treatments that address the needs of individual patients prove more effective and pleasing; thus, this is driving the need for more personal options.
  • Digital Health Integration: This has been an increasingly emerging opportunity in the use of digital health technologies for disease monitoring and management. Development and integration of wearable devices and mobile apps can be made in support of better patient outcomes and treatment adherence.
  • Patient Support Programs: Better-designed patient support programs, including education, self-management tools, and psychological support, have the potential to improve adherence to treatment and quality of life. Better investing in these programs would lead to overall better management of the disease.

All these opportunities are changing the dimensions of innovation, accessibility, and quality care, thereby shaping the Ankylosing Spondylitis treatment market.

Ankylosing Spondylitis Treatment Market Driver and Challenges

The growth of the market and challenges pertaining to the Ankylosing Spondylitis treatment market include drivers and restraints, which further comprise technology advancements, economic factors, and regulatory considerations.

The factors responsible for driving the ankylosing spondylitis treatment market include:

1. Innovation in Biologics: New biologics targeting TNF and IL-17 represent one of the drivers for market growth, promising more efficient and safer treatments that address unmet needs and improve outcomes.

2. Penetration of Biosimilars: Biosimilars are going to make treatments for AS more affordable and accessible, hence this trend is expanding the market, making advanced therapies available to a broader patient population.

3. Development of Personalized Medicine: Development of personalized treatment approaches using genetic and molecular profiling will enhance the efficacy of treatments. These advances are driving demand for tailored therapies that improve patient outcomes.

4. Increased Awareness and Penetration: Greater awareness and accessibility regarding AS treatments in developing markets drive a bigger share of the market. Improved healthcare infrastructure and education among patients enable better management of the disease.

Challenges in the ankylosing spondylitis treatment market are:

1. High Cost of New Therapies: The high cost of novel biologic drugs and personalized treatments makes them out of reach for some. It is a crucial aspect that requires attention to ensure the dissemination and expansion of such treatments.

2. Regulatory Hurdles: With newer treatment options still coming up, the regulatory requirements for these newer treatments will be challenging to work with. The observance of regulations regarding compliance allows market entry and product approval.

3. Market Competition: There is huge competition among pharmaceutical companies, which affects the share and price of the market. This demands endless innovation and differentiation within products and services to stay competitive.

These drivers and challenges are influencing technological advancement, market dynamic, and regulatory compliances, hence shaping the Ankylosing Spondylitis treatment market. To effectively address these factors becomes crucial for capitalizing on the opportunities and navigating complexities in the market.

List of Ankylosing Spondylitis Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies ankylosing spondylitis treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ankylosing spondylitis treatment companies profiled in this report include-

  • Novartis
  • Amgen
  • Boehringer Ingelheim International
  • UCB Biopharma
  • AbbVie

Ankylosing Spondylitis Treatment by Segment

The study includes a forecast for the global ankylosing spondylitis treatment by drug class, distribution channel, and region.

Ankylosing Spondylitis Treatment Market by Drug Class [Analysis by Value from 2018 to 2030]:

  • NSAIDs
  • TNF Inhibitors
  • Others

Ankylosing Spondylitis Treatment Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Ankylosing Spondylitis Treatment Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Ankylosing Spondylitis Treatment Market

Developments in the ankylosing spondylitis treatment market are unceasing, with growing drug development and personalized medicine. The recent innovation pipeline is targeted at unmet needs and improving patient outcomes. Development taking place in the United States, China, Germany, India, and Japan reflects considerable improvement both in pharmaceutical treatments and supportive care strategies.

  • United States: A number of new biologic agents targeting TNF and IL-17 have been made available over the last two decades. These newer agents boast better efficacy and safety profiles that have considerably advanced the care of AS patients.
  • China: China is also working to increase its treatment options by introducing biosimilars to established biologics treatments. This would result in increased access and affordability for the AS patients, thus contributing to a wider adoption of effective therapies.
  • Germany: There is an increasing trend of research and development studies in Germany on newer drug targets and personalized modes of treatment. Better genetic and molecular studies are leading to the emergence of better treatment options for AS.
  • India: There is increasing awareness and utilization of newer modes of treatment for AS in India. Readily available TNF inhibitors and better health infrastructure are improving accessibility and availability for the patients.
  • Japan: Japan is focusing on the integration of new therapies coupled with digital health in the management of AS. Of late, wearables are being utilized to monitor disease progression and treatment outcomes.

Features of the Global Ankylosing Spondylitis Treatment Market

Market Size Estimates: Ankylosing spondylitis treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Ankylosing spondylitis treatment market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Ankylosing spondylitis treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, distribution channels, and regions for the ankylosing spondylitis treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ankylosing spondylitis treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q1. What is the ankylosing spondylitis treatment market size?

Answer: The global ankylosing spondylitis treatment market is expected to reach an estimated $8.4 billion by 2030.

Q2. What is the growth forecast for ankylosing spondylitis treatment market?

Answer: The global ankylosing spondylitis treatment market is expected to grow with a CAGR of 6.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the ankylosing spondylitis treatment market?

Answer: The major drivers for this market are rising occurrence of ankylosing spondylitis, growing awareness and diagnosis of condition, and advancement in ankylosing spondylitis therapy.

Q4. What are the major segments for ankylosing spondylitis treatment market?

Answer: The future of the ankylosing spondylitis treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.

Q5. Who are the key ankylosing spondylitis treatment market companies?

Answer: Some of the key ankylosing spondylitis treatment companies are as follows:

  • Novartis
  • Amgen
  • Boehringer Ingelheim International
  • UCB Biopharma
  • AbbVie

Q6. Which ankylosing spondylitis treatment market segment will be the largest in future?

Answer: Lucintel forecasts that NSAIDs will remain the larger segment over the forecast period due to growth of ankylosing spondylitis.

Q7. In ankylosing spondylitis treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growth of geriatric population and supportive government initiatives.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the ankylosing spondylitis treatment market by drug class (NSAIDs, TNF inhibitors, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
  • Market Report

Table of Contents

1. Executive Summary

2. Global Ankylosing Spondylitis Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Ankylosing Spondylitis Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Ankylosing Spondylitis Treatment Market by Drug Class
    • 3.3.1: NSAIDs
    • 3.3.2: TNF Inhibitors
    • 3.3.3: Others
  • 3.4: Global Ankylosing Spondylitis Treatment Market by Distribution Channel
    • 3.4.1: Hospital Pharmacy
    • 3.4.2: Retail Pharmacy
    • 3.4.3: Online Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Ankylosing Spondylitis Treatment Market by Region
  • 4.2: North American Ankylosing Spondylitis Treatment Market
    • 4.2.1: North American Ankylosing Spondylitis Treatment Market by Drug Class: NSAIDs, TNF Inhibitors, and Others
    • 4.2.2: North American Ankylosing Spondylitis Treatment Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
  • 4.3: European Ankylosing Spondylitis Treatment Market
    • 4.3.1: European Ankylosing Spondylitis Treatment Market by Drug Class: NSAIDs, TNF Inhibitors, and Others
    • 4.3.2: European Ankylosing Spondylitis Treatment Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
  • 4.4: APAC Ankylosing Spondylitis Treatment Market
    • 4.4.1: APAC Ankylosing Spondylitis Treatment Market by Drug Class: NSAIDs, TNF Inhibitors, and Others
    • 4.4.2: APAC Ankylosing Spondylitis Treatment Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
  • 4.5: ROW Ankylosing Spondylitis Treatment Market
    • 4.5.1: ROW Ankylosing Spondylitis Treatment Market by Drug Class: NSAIDs, TNF Inhibitors, and Others
    • 4.5.2: ROW Ankylosing Spondylitis Treatment Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Ankylosing Spondylitis Treatment Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Ankylosing Spondylitis Treatment Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Ankylosing Spondylitis Treatment Market by Region
  • 6.2: Emerging Trends in the Global Ankylosing Spondylitis Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Ankylosing Spondylitis Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ankylosing Spondylitis Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: Amgen
  • 7.3: Boehringer Ingelheim International
  • 7.4: UCB Biopharma
  • 7.5: AbbVie